Arrowstreet Capital’s Stoke Therapeutics STOK Stock Holding History

Arrowstreet Capital’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,337	Closed	-$164K	–	1971
2024 Q3	$164K	Buy	+13,337	New	+$189K	﹤0.01%	1662

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Arrowstreet Capital's STOK Position: Q4 2024 in Review

Arrowstreet Capital sold out of Stoke Therapeutics (STOK) in Q4 2024, closing a stake of 13,337 shares — an estimated $164K sold.

Arrowstreet Capital first reported a position in STOK in Q3 2024 and held it in 1 quarter. The position peaked at $164K in Q3 2024. 130 funds tracked by Wall St. Rank hold STOK as of Q4 2024.

Arrowstreet Capital reported no remaining Stoke Therapeutics position as of Q4 2024 after selling out during the quarter.
Arrowstreet Capital sold 13,337 Stoke Therapeutics shares in Q4 2024, an estimated $164K.
Arrowstreet Capital first reported a position in Stoke Therapeutics in Q3 2024 and held it in 1 quarter.
Arrowstreet Capital's Stoke Therapeutics position peaked at $164K in Q3 2024.
130 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2024.

Based on Arrowstreet Capital's 13F filing for Q4 2024, filed 12 Feb 2025.